{"id":59055,"date":"2024-02-28T05:40:03","date_gmt":"2024-02-28T05:40:03","guid":{"rendered":"https:\/\/medsname.com\/qutan-sr-400\/"},"modified":"2026-04-30T10:24:04","modified_gmt":"2026-04-30T10:24:04","slug":"qutan-sr-400","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nb\/product\/qutan-sr-400\/","title":{"rendered":"Qutan SR 400"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Raskt svar<\/h3>\n

Qutan SR 400 (Quetiapine 400 mg SR, extended\/sustained-release) is an atypical antipsychotic for schizophrenia, bipolar mania, bipolar depression, MDD adjunct, and GAD adjunct. Strongly sedating and metabolically heavy \u2014 but uniquely effective for bipolar depression. Often misused as a “sleeping pill” \u2014 discouraged because of metabolic burden.<\/p>\n<\/div>\n

\nHva du f\u00e5r med MedsBase:<\/strong> WHO-GMP-sertifisert produsent \u00b7 Diskret emballasje \u00b7 Verdensomspennende levering \u00b7 1 400+ verifiserte kundeanmeldelser<\/a>\n<\/div>\n

\ud83d\udce6 Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis pakken din ikke ankommer innen 20 virkedager, sender vi ny.<\/p>\n

Hvorfor bestille fra MedsBase<\/h3>\n

Qutan SR 400 at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Reshipment Assurance Policy<\/a> \u2014 20 virkedagers leveringsvindu eller vi sender p\u00e5 nytt uten ekstra kostnad \u2014 og kvalifiserer for v\u00e5rt kundelojalitetsprogram<\/a>. Verdensomspennende shipping er tilgjengelig til de fleste destinasjoner.<\/p>\n

What Qutan SR 400 is and how it works<\/h2>\n

Qutan SR 400 is a quetiapine extended\/sustained-release tablet supplied by Cipla. Available strengths: 400 mg SR<\/strong>. Quetiapine has loose D2 binding (rapid dissociation explains low EPS), strong 5-HT2A antagonism, very strong H1 antihistamine action (sedation, weight gain), \u03b11-adrenergic antagonism (orthostasis), and \u03b12 antagonism. Its active metabolite, norquetiapine, has noradrenaline transporter inhibition \u2014 the basis for the antidepressant effect in bipolar depression.<\/p>\n

The SR\/XR formulation is dosed once daily, generally at bedtime. The IR formulation is split BID. SR has slightly lower peak sedation and may be better tolerated for daytime function.<\/p>\n

Indikasjoner og dosering<\/h2>\n\n\n\n\n\n\n\n\n\n\n
Indikasjon<\/th>\nStartdose<\/th>\nM\u00e5ldose<\/th>\nMaks<\/th>\n<\/tr>\n<\/thead>\n
Schizophrenia (SR)<\/td>\n50 mg HS<\/td>\n400\u2013800 mg\/dag<\/td>\n800 mg<\/td>\n<\/tr>\n
Bipolar mania<\/td>\n50 mg BID (IR) or 300 mg HS (SR)<\/td>\n400\u2013800 mg\/dag<\/td>\n800 mg<\/td>\n<\/tr>\n
Bipolar depression<\/td>\n50 mg HS<\/td>\n300 mg HS<\/td>\n600 mg<\/td>\n<\/tr>\n
MDD adjunct (SR)<\/td>\n50 mg HS<\/td>\n150\u2013300 mg HS<\/td>\n300 mg<\/td>\n<\/tr>\n
GAD adjunct (off-label)<\/td>\n50 mg HS<\/td>\n50\u2013150 mg HS<\/td>\n\u2014<\/td>\n<\/tr>\n
Eldre voksne<\/td>\n25 mg HS<\/td>\n50\u2013200 mg\/dag<\/td>\netter toleranse<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Viktige sikkerhetshensyn<\/h2>\n
\nFDA black-box \u2014 demensrelatert psykose<\/strong><\/p>\n

Alle atypiske antipsykotika b\u00e6rer en FDA black-box advarsel for \u00f8kt d\u00f8delighet (hovedsakelig kardiovaskul\u00e6r og infeksi\u00f8s) n\u00e5r de brukes til \u00e5 behandle atferdsforstyrrelser hos eldre med demens. Atypiske antipsykotika er ikke godkjent for demensrelatert psykose eller agitasjon<\/strong>. Bruk i denne populasjonen er off-label, siste utvei, tidsbegrenset, og krever eksplisitt risikovurderingssamtale.<\/p>\n<\/div>\n

\nTung metabolsk belastning<\/strong><\/p>\n

Weight gain, insulin resistance, dyslipidaemia \u2014 second only to olanzapine and clozapine among atypicals. Mandatory monitoring at baseline, 12 weeks, then 6-monthly: weight, fasting glucose \/ HbA1c, fasting lipids, BP. Counsel about diet\/exercise from initiation.<\/p>\n<\/div>\n

\nOrthostatisk hypotensjon<\/strong><\/p>\n

\u03b11 antagonism produces orthostatic hypotension, particularly in older adults and at initiation. Titrate slowly. Check sitting and standing BP at follow-up.<\/p>\n<\/div>\n

\n“Off-label sleep aid” \u2014 discouraged<\/strong><\/p>\n

Low-dose quetiapine (25\u201350 mg HS) is widely used off-label as a hypnotic. The metabolic burden is the same regardless of indication \u2014 patients on quetiapine for sleep gain weight and develop insulin resistance just as much as patients on quetiapine for psychosis. Dedicated hypnotics (Z-drugs, low-dose doxepin, melatonin agonists, behavioural sleep therapy) are usually safer choices for primary insomnia.<\/p>\n<\/div>\n

\nSuicidality (under-25, MDD adjunct use)<\/strong><\/p>\n

N\u00e5r brukt som tilskudd til antidepressiva, gjelder advarselen om \u00f8kt selvmordsfare for personer under 25 \u00e5r.<\/p>\n<\/div>\n

Vanlige bivirkninger<\/h2>\n